IL6 and osteoporosis: However, the major problem for the administration of broad-spectrum anti-inflammation drugs is the significant side effects of the drugs such as hyperglycemia, hypertension, and osteoporosis (14, 15), while the major problems for the administration of the agents targeting at IL-6 signaling pathways include serious infection (16), loss of efficacy and/or immune-mediated adverse reactions (17) and relatively high cost of the drug.